REQUEST A DEMO
Total
USD $0.00
Search more companies

UAB Entafarma (Lithuania)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers | Other Miscellaneous Nondurable Goods Merchant Wholesalers
Secondary Activities: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers | Other Chemical and Allied Products Merchant Wholesalers
Full name: UAB Entafarma Profile Updated: January 01, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Russian Download a sample report

UAB Entafarma is a company based in Lithuania, with its head office in Sirvintos. The company operates in the Drugs and Druggists' Sundries Merchant Wholesalers sector. It was incorporated on February 06, 2001. It currently has a total number of 164 (2025) employees. In its most recent financial highlights, the company reported a net sales revenue increase of 13.18% in 2024. In 2024, UAB Entafarma’s net profit margin increased by 0.56%.

Headquarters
Jauniunu sen. Klonenu vs. 1
Sirvintos; Vilnius county; Postal Code: LT-19156

Contact Details: Purchase the UAB Entafarma report to view the information.

Website: http://www.entafarma.lt

Basic Information
Total Employees:
Purchase the UAB Entafarma report to view the information.
Registered Capital:
Purchase the UAB Entafarma report to view the information.
Financial Auditors:
Purchase the UAB Entafarma report to view the information.
Incorporation Date:
February 06, 2001
Key Executives
Purchase this report to view the information.
Member of the Management Board
Company Performance
Financial values in the chart are available after UAB Entafarma report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
13.18%
Total Operating Revenue
13.18%
Net Profit/Loss for the Period
29.05%
Total Equity
18.43%
Net Profit Margin
0.56%
Return on Equity (ROE)
1.47%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?